Previous 10 | Next 10 |
Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant Topline readout of active disease group in AML trial expected in Q1 2022 PR Newswire HOUSTON , March 3, 2021 /PRNewswire/...
Marker has treated over 100 patients with their unique Multi TAA technology and so far has demonstrated strong efficacy in patients in AML, Lymphoma, Multiple Myeloma, and ALL. In lymphoma, 40% of treated patients, most of whom had at least 3-5 prior treatments and relapsed after a me...
Clinical-stage immuno-oncology company Marker Therapeutics' (MRKR) shares jump ~10% premarket after it announces that it has completed the construction and qualification of its cGMP manufacturing facility in Houston, TX.The facility will allow production of MultiTAA-specif...
Acorda Therapeutics (ACOR) +54% after announcing agreement for sale of manufacturing operations and long-term global supply agreement.Summit Midstream Partners (SMLP) +45% after winning FERC construction OK.WiMi Hologram Cloud (WIMI) +38% on obtaining a patent for a 3D holograp...
Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates -- Company expects to complete tech transfer and treat first patient with MT-401 manufactured in new cGMP facility in H1 ...
My Size (MYSZ) -21% after pricing equity offering.Titan Medical (TMDI) -18% after announcing $10M bought deal offering.Synthetic Biologics (SYN) -16%.Brickell Biotech (BBI) -10%.Bionano Genomics (BNGO) -8%.Marker Therapeutics (MRKR) -7%.Clearside Biomedical (CLSD) ...
Aileron Therapeutics (ALRN) +73%.Broadway Financial Corporation (BYFC) +55% after regulatory approvals for merger with CFBanc Corporation.Atlantic American Corporation (AAME) +43%.Marker Therapeutics (MRKR) +30% after FDA lifted the partial clinical hold on it's Phase 2 trial.Cyclo ...
The FDA has lifted the partial clinical hold on Marker Therapeutics' (MRKR) Phase 2 trial, evaluating MT-401, the company's lead multi-tumor-associated antigen (MultiTAA)-specific T cell product candidate for the treatment of post-transplant acute myeloid leukemia ((AML)).Marker pre...
Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial PR Newswire HOUSTON , Jan. 5, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the developm...
Marker Therapeutics, Inc. (MRKR) Q3 2020 Earnings Conference Call November 09, 2020, 17:00 ET Company Participants Anthony Kim - CFO Peter Hoang - President, CEO & Director Mythili Koneru - Chief Medical Officer Juan Vera - Chief Development Officer & Director Conference Call Particip...
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...